These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 21212673)
41. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Fox K; Ferrari R; Tendera M; Steg PG; Ford I; Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146 [TBL] [Abstract][Full Text] [Related]
42. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Matsumoto T; Wada A; Tsutamoto T; Ohnishi M; Isono T; Kinoshita M Circulation; 2003 May; 107(20):2555-8. PubMed ID: 12742989 [TBL] [Abstract][Full Text] [Related]
49. Anti-ischaemic effect of ivabradine. Ferrari R; Cargnoni A; Ceconi C Pharmacol Res; 2006 May; 53(5):435-9. PubMed ID: 16644235 [TBL] [Abstract][Full Text] [Related]
50. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). Tendera M; Talajic M; Robertson M; Tardif JC; Ferrari R; Ford I; Steg PG; Fox K; Am J Cardiol; 2011 Mar; 107(6):805-11. PubMed ID: 21247517 [TBL] [Abstract][Full Text] [Related]
51. Effects of verapamil, zatebradine, and E-4031 on the pacemaker location and rate in response to sympathetic stimulation in dog hearts. Furukawa Y; Miyashita Y; Nakajima K; Hirose M; Kurogouchi F; Chiba S J Pharmacol Exp Ther; 1999 Jun; 289(3):1334-42. PubMed ID: 10336524 [TBL] [Abstract][Full Text] [Related]
52. Effect of long-term heart rate reduction by If current inhibition on pressure overload-induced heart failure in rats. Ciobotaru V; Heimburger M; Louedec L; Heymes C; Ventura-Clapier R; Bedossa P; Escoubet B; Michel JB; Mercadier JJ; Logeart D J Pharmacol Exp Ther; 2008 Jan; 324(1):43-9. PubMed ID: 17901295 [TBL] [Abstract][Full Text] [Related]
53. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine. Canet E; Lerebours G; Vilaine JP Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947 [TBL] [Abstract][Full Text] [Related]
54. Ivabradine improves left ventricular function during chronic hypertension in conscious pigs. Rienzo M; Melka J; Bizé A; Sambin L; Jozwiak M; Su JB; Hittinger L; Berdeaux A; Ghaleh B Hypertension; 2015 Jan; 65(1):122-9. PubMed ID: 25350985 [TBL] [Abstract][Full Text] [Related]
55. Cardioprotective effects of the Ιf current inhibition by ivabradine during cardiac dysfunction. Su JB Curr Pharm Biotechnol; 2014; 14(14):1213-9. PubMed ID: 24831809 [TBL] [Abstract][Full Text] [Related]
56. Heart rate reduction by pharmacological If current inhibition. Cargnoni A; Ceconi C; Stavroula G; Ferrari R Adv Cardiol; 2006; 43():31-44. PubMed ID: 16936470 [TBL] [Abstract][Full Text] [Related]
57. If current inhibition: cellular basis and physiology. Mangoni ME; Marger L; Nargeot J Adv Cardiol; 2006; 43():17-30. PubMed ID: 16936469 [TBL] [Abstract][Full Text] [Related]